FDA hands Seat­tle Ge­net­ics its 5th OK for Ad­cetris. But can they ac­tu­al­ly sell it for front­line Hodgkin lym­phoma?

As ex­pect­ed, the FDA has come through with their 5th ap­proval for Seat­tle Ge­net­ics’ $SGEN Ad­cetris. And now the com­pa­ny can start to prove whether they can squeeze some ad­di­tion­al rev­enue out of it.

At ASH last fall Seat­tle Ge­net­ics CEO Clay Sie­gall was adamant that the two-year mod­i­fied pro­gres­sion-free sur­vival rate of 82.1% com­pared to 77.2% in the con­trol arm of the ECH­E­LON-1 front­line Hodgkin lym­phoma study — a 4.9 point, or 6%, im­prove­ment — would get physi­cians’ at­ten­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER